GPR40 Agonist Compounds for Type 2 Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 2 diabetes, such as biguanides, glitazones, insulin secretagogues, and DPP-4 inhibitors, have limitations including side effects like hypoglycemia, weight gain, and negative impacts on lipid profiles, and there is a need for more effective and safer pharmacological options that target G-protein coupled receptor 40 (GPR40) for improved glucose and lipid metabolism.
Innovation Solution
Development of novel substituted compounds that act as agonists of G-protein coupled receptor 40 (GPR40), which are designed to treat Type 2 diabetes, insulin resistance, and related conditions by enhancing glucose and lipid metabolism without the risks of hypoglycemia or significant side effects, and can be used alone or in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diabetes treatments (biguanides, glitazones, insulin secretagogues, DPP-4 inhibitors) are used, then glucose metabolism is improved, but side effects occur including hypoglycemia, weight gain, and negative impacts on lipid profiles
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (Formula I) that target GPR40 receptors. These structural parameter changes in the pharmaceutical agents enable improved glucose metabolism control while avoiding the harmful side effects associated with conventional diabetes treatments, as the new compounds interact with a different biological target (GPR40) compared to existing therapies.
2Reliability
If physical exercise and dietary reduction are implemented, then diabetic condition is dramatically improved, but compliance is very poor due to sedentary lifestyles and excess food consumption
Solution Approach 1:
The patent employs an intermediary approach by introducing GPR40 agonist compounds as a pharmacological mediator that facilitates glucose metabolism improvement without requiring direct patient behavior changes. These compounds act as intermediaries between the desired therapeutic outcome and the patient's lifestyle, enabling metabolic benefits to be achieved through medication rather than through difficult lifestyle modifications, thereby significantly improving treatment compliance.
3Reliability
If GPR40 agonist compounds are developed, then safer and more effective treatment is achieved, but device complexity increases due to novel compound synthesis requirements
Solution Approach 1:
The patent applies segmentation by dividing the complex GPR40 agonist compound into definable structural components represented by Formula I, where various substituents (R1, R2, R3, R4, R5, R6, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, RL) can be independently selected from specified groups. This segmented structural approach allows systematic synthesis and optimization of multiple compound variants while maintaining the core GPR40 agonist activity, thereby managing synthesis complexity through modular design.
Data Source
AI summary
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.